Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRizatriptan benzoate is a 5-HT1B/1D agonist. Antimigraine agent; attenuates effects of CGRP on light aversion in mice. Orally bioavailable.
Rizatriptan benzoate is also offered as part of the Tocriscreen FDA-Approved Drugs. 了解 Tocris 化合物库的更多信息。
分子量 | 391.47 |
公式 | C15H19N5.C7H6O2 |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 145202-66-0 |
PubChem ID | 77997 |
InChI Key | JPRXYLQNJJVCMZ-UHFFFAOYSA-N |
Smiles | CN(CCC2=CNC1=CC=C(CN3N=CN=C3)C=C12)C.O=C(C4=CC=CC=C4)O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Kaiser et al (2012) Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT1B/D agonist. J.Neurosci. 32 15439 PMID: 23115181
Street et al (1995) Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors. J.Med.Chem. 38 1799 PMID: 7752204
关键词: Rizatriptan benzoate, Rizatriptan benzoate supplier, selective, 5-HT, serotonin, 5-HT1D, 5-HT1B, receptors, agonists, Rizatriptan, benzoate, serotonergics, MK462, MK, 462, Receptors, 5136, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Rizatriptan benzoate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.